NZ595252A - Biofilm treatment - Google Patents

Biofilm treatment

Info

Publication number
NZ595252A
NZ595252A NZ595252A NZ59525208A NZ595252A NZ 595252 A NZ595252 A NZ 595252A NZ 595252 A NZ595252 A NZ 595252A NZ 59525208 A NZ59525208 A NZ 59525208A NZ 595252 A NZ595252 A NZ 595252A
Authority
NZ
New Zealand
Prior art keywords
inhibiting agent
biofilm treatment
inhibiting
gingivalis
biofilm
Prior art date
Application number
NZ595252A
Other languages
English (en)
Inventor
Stuart Geoffrey Dashper
Eric Charles Reynolds
Paul David Veith
Ching Seng Ang
Original Assignee
Oral Health Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ595252(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2007903788A external-priority patent/AU2007903788A0/en
Application filed by Oral Health Australia Pty Ltd filed Critical Oral Health Australia Pty Ltd
Publication of NZ595252A publication Critical patent/NZ595252A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ595252A 2007-07-12 2008-07-11 Biofilm treatment NZ595252A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007903788A AU2007903788A0 (en) 2007-07-12 Biofilm treatment
NZ582474A NZ582474A (en) 2007-07-12 2008-07-11 Use of oxantel, morantel or thiabendazole for preventing, inhibiting or reducing a p. gingivalis biofilm

Publications (1)

Publication Number Publication Date
NZ595252A true NZ595252A (en) 2013-11-29

Family

ID=40228120

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ595252A NZ595252A (en) 2007-07-12 2008-07-11 Biofilm treatment
NZ582474A NZ582474A (en) 2007-07-12 2008-07-11 Use of oxantel, morantel or thiabendazole for preventing, inhibiting or reducing a p. gingivalis biofilm

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ582474A NZ582474A (en) 2007-07-12 2008-07-11 Use of oxantel, morantel or thiabendazole for preventing, inhibiting or reducing a p. gingivalis biofilm

Country Status (13)

Country Link
US (2) US8241611B2 (enExample)
EP (2) EP2638905B1 (enExample)
JP (1) JP5476297B2 (enExample)
KR (2) KR101614938B1 (enExample)
CN (2) CN103357014A (enExample)
AU (1) AU2008274906B2 (enExample)
CA (1) CA2693695C (enExample)
DK (1) DK2175851T3 (enExample)
ES (2) ES2714008T3 (enExample)
NZ (2) NZ595252A (enExample)
PL (1) PL2175851T3 (enExample)
SG (1) SG183016A1 (enExample)
WO (1) WO2009006699A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
CA2652957A1 (en) 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
CN102652831A (zh) 2007-07-12 2012-09-05 口腔健康澳洲私人有限公司 生物膜的免疫治疗
EP2638905B1 (en) 2007-07-12 2019-01-16 Oral Health Australia Pty Ltd Biofilm treatment
EP2328914B1 (en) 2008-08-29 2017-05-10 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
AR076179A1 (es) * 2009-04-01 2011-05-26 Colgate Palmolive Co Composicion dentifrica no acuosa con vidrio bioaceptable y bioactivo y metodos de uso y fabricacion de la misma
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
WO2011105869A2 (ko) * 2010-02-26 2011-09-01 주식회사 나이벡 치아의 접합능을 향상시키기 위한 치과용 클린저 조성물
MY162557A (en) 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
WO2012027690A1 (en) * 2010-08-27 2012-03-01 The Regents Of The University Of Michigan Control of biofilm formation
US9549904B2 (en) 2012-06-06 2017-01-24 Thomas Bryan Method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin
US9480669B2 (en) 2015-01-06 2016-11-01 The Regents Of The University Of California Method of destroying and preventing bacterial and fungal biofilm by amino acid infusion
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US9795809B2 (en) 2013-12-23 2017-10-24 Embro Corporation Use of moss to improve dental health
EP3322408B1 (en) 2015-07-14 2022-06-08 The Research Institute at Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (en) * 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
EP3565589A1 (en) 2017-01-04 2019-11-13 Research Institute at Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
WO2018226987A1 (en) 2017-06-07 2018-12-13 The Regents Of The University Of California Compositions for treating fungal and bacterial biofilms and methods of using the same
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
JP2022504139A (ja) 2018-10-05 2022-01-13 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのｈｍｇｂ１タンパク質誘導体
US12226386B2 (en) 2018-12-03 2025-02-18 The Regents Of The University Of California Compositions and methods for treating biofilms
US12109176B1 (en) 2023-04-20 2024-10-08 Thomas Bryan Effect of glycerol on biofilm forming bacteria and fungi that changes the microbes sensitivity to pro and anti-biofilm non-toxic, non-bonded plasma amino acids and amino acid derivatives

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US5210035A (en) 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5830710A (en) 1988-09-08 1998-11-03 University Of Florida Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease
WO1994027606A1 (en) * 1993-05-28 1994-12-08 Unisearch Limited Method of treating helicobacter pylori infection
AU6983594A (en) 1993-06-28 1995-01-17 Lion Corporation Composition for oral cavity
US5523390A (en) 1993-09-10 1996-06-04 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
ATE242331T1 (de) 1993-09-10 2003-06-15 Univ Georgia Res Found Porphyromonas gingivalis arginin-spezifische proteinase kodierende sequenzen
US6017532A (en) 1993-09-10 2000-01-25 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
US5475097A (en) 1993-10-21 1995-12-12 University Of Georgia Research Foundation, Inc. Lysine-specific Porphyromonas gingivalis proteinase
JPH0797395A (ja) 1993-09-28 1995-04-11 Kyowa Medex Co Ltd ポルフイロモナス・ジンジバリス線毛蛋白質の配列を含有するペプチド類及びその用途
DE69527514T2 (de) 1994-03-29 2003-04-03 Kyowa Hakko Kogyo Co., Ltd. Gen eines zelloberflächenpolypeptids
AUPN627595A0 (en) 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
JP2000507245A (ja) 1996-03-22 2000-06-13 ユニバーシティー オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド Ｐｏｒｐｈｙｒｏｍｏｎａｓ ｇｉｎｇｉｖａｌｉｓペプチドを含む免疫原性組成物および方法
AUPN901296A0 (en) 1996-03-29 1996-04-26 University Of Melbourne, The Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
CA2313823A1 (en) * 1997-12-10 1999-06-17 Csl Limited Porphorymonas gingivalis polypeptides and nucleotides
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
AUPP083997A0 (en) 1997-12-10 1998-01-08 Csl Limited Porphyromonas gingivalis nucleotides
US6444799B1 (en) 1997-12-31 2002-09-03 Csl Limited P. gingivalis polynucleotides and uses thereof
AUPP893999A0 (en) 1999-03-01 1999-03-25 Csl Limited Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis
JP2003534235A (ja) * 1999-05-12 2003-11-18 ザ ゼネラル ホスピタル コーポレーション バイオフイルムの透過性化
GB9913437D0 (en) 1999-06-09 1999-08-11 Medical Res Council Fusion proteins
AUPQ485999A0 (en) 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
AUPQ718200A0 (en) 2000-04-28 2000-05-25 Csl Limited Porphyromonas gingivalis recombinant proteins and truncations
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6726898B2 (en) * 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US20030083287A1 (en) 2000-11-30 2003-05-01 Burgess Nicola A. ginS
AUPR575401A0 (en) * 2001-06-18 2001-07-12 Unisearch Limited Method of causing sloughing
GB2381449A (en) * 2001-10-31 2003-05-07 Smithkline Beecham Plc Oral hygiene compositions comprising an electron acceptor
JP2003192616A (ja) 2001-12-27 2003-07-09 Univ Nihon 歯周病用ｄｎａワクチン
JP2003286191A (ja) 2002-03-27 2003-10-07 Univ Nihon 歯周病用粘膜免疫ワクチン
US20070036734A1 (en) 2003-03-17 2007-02-15 Kirin Beer Kabushiki Kaisha Therapeutic agent for periodontal disease
ATE495189T1 (de) 2003-08-15 2011-01-15 Univ Florida Die identifikation von polynukleotiden von porphyromonas gingivalis-virulenz zur diagnose, behandlung und beobachtung von periodontalerkrankungen
US7424370B2 (en) 2004-02-06 2008-09-09 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
US20070098649A1 (en) * 2004-03-22 2007-05-03 The Board Of Trustees Of The University Of Illinois Method and composition for controlling oral pathogens
NZ554331A (en) 2004-09-23 2009-04-30 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2008016385A2 (en) 2006-01-20 2008-02-07 The University Of Washington Deacylase polypeptides, deacylase polynucleotides, and methods of use thereof
CA2652957A1 (en) * 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
WO2008124646A2 (en) 2007-04-06 2008-10-16 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Use of amyloid proteins as vaccine scaffolds
EP2638905B1 (en) 2007-07-12 2019-01-16 Oral Health Australia Pty Ltd Biofilm treatment
CN102652831A (zh) 2007-07-12 2012-09-05 口腔健康澳洲私人有限公司 生物膜的免疫治疗
EP2328914B1 (en) 2008-08-29 2017-05-10 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
WO2010144968A1 (en) * 2009-06-19 2010-12-23 Oral Health Australia Pty Ltd Casein derived protease inhibitory peptides

Also Published As

Publication number Publication date
EP2175851A4 (en) 2011-03-16
US20130028847A1 (en) 2013-01-31
DK2175851T3 (da) 2013-07-15
US20100209362A1 (en) 2010-08-19
KR20160013240A (ko) 2016-02-03
US8241611B2 (en) 2012-08-14
CN103357014A (zh) 2013-10-23
KR20100051656A (ko) 2010-05-17
KR101614938B1 (ko) 2016-04-22
PL2175851T3 (pl) 2013-11-29
CN101842097A (zh) 2010-09-22
EP2638905A3 (en) 2014-03-05
ES2714008T3 (es) 2019-05-24
ES2432690T3 (es) 2013-12-04
JP5476297B2 (ja) 2014-04-23
EP2638905B1 (en) 2019-01-16
US8895019B2 (en) 2014-11-25
AU2008274906A1 (en) 2009-01-15
CA2693695A1 (en) 2009-01-15
CA2693695C (en) 2016-06-07
EP2175851A1 (en) 2010-04-21
AU2008274906B2 (en) 2013-11-07
NZ582474A (en) 2012-03-30
EP2638905A2 (en) 2013-09-18
HK1143530A1 (en) 2011-01-07
JP2010532765A (ja) 2010-10-14
CN101842097B (zh) 2013-06-19
WO2009006699A1 (en) 2009-01-15
EP2175851B1 (en) 2013-05-15
SG183016A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
EP1880719A3 (en) Composition for prophylaxis or treatment of urinary system infection and method thereof
WO2008127275A3 (en) Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
MX358018B (es) Inhibición de organismos de biopelícula.
IL160420A0 (en) Treating or preventing diabetes with cannabidiol
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
MX2012006629A (es) Microorganismos probioticos como agentes activos contra cambios en microrelieve de la piel.
MX2007005678A (es) Azucares y alcoholes de azucar para inhibir y/o tratar la infeccion vaginal.
EP2638905A3 (en) Biofilm treatment
EP2494059A4 (en) USE OF METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY
WO2007130655A3 (en) Phage derived antimicrobial activities
TN2009000211A1 (en) Antiviral composition and method of use
MX2009005795A (es) Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona.
WO2006063176A3 (en) Inhibition of biofilm formation using bacteriophage
ATE499091T1 (de) Antimikrobielle materialien
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2007112121A3 (en) Tetracycline compounds and methods of treatment
MX372951B (es) Composiciones y metodos de tratamiento que comprenden ceftarolina.
PL1919466T3 (pl) Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
WO2003059254A3 (en) Prevention and treatment of atherosclerosis and restenosis
EP3939599A3 (en) Silicate containing compositions and methods of treatment
DK1984001T3 (da) Fikseret dosisassociation af phytat og zink
TW200738700A (en) HIV integrase inhibitors
BRPI0610722A2 (pt) métodos para tratar uma infecção bacteriana, para prevenir, tratar ou melhorar o tratamento eficaz de mrsa, para inibir o crescimento de um micróbio, e para selecionar um agente terapêutico de mrsa útil pata tratar uma infcção bacteriana, e, composição

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 JUL 2015 BY CPA GLOBAL

Effective date: 20140602

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUL 2016 BY LEA

Effective date: 20150629

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUL 2017 BY LEA SKYLLERSTEDT

Effective date: 20160706

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUL 2018 BY CPA GLOBAL (PATRAFEE)

Effective date: 20170628

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUL 2019 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20180629

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUL 2020 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20190626

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUL 2021 BY CPA GLOBAL

Effective date: 20200604

LAPS Patent lapsed